



MARYLAND
Prescription Drug Affordability Board

16900 Science Drive
Suite 112-114
Bowie, MD 20715
pdab.maryland.gov

March 13, 2026

The Honorable Heather Bagnall
Chair, House Health Committee
241 Taylor House Office Building
Annapolis, Maryland 21401

RE: House Bill 1440 – Maryland Medical Assistance Program and Health Insurance - Coverage and Utilization Review - Drugs Reviewed by the Prescription Drug Affordability Board

Dear Chair Bagnall and Committee Members:

The Maryland Prescription Drug Affordability Board (PDAB) respectfully submits this letter of opposition for House Bill (HB) 1440 – Maryland Medical Assistance Program and Health Insurance - Coverage and Utilization Review - Drugs Reviewed by the Prescription Drug Affordability Board. HB 1440 imposes certain restrictions on MCOs, insurers, HMOs and others based solely on whether the PDAB undertakes a cost review study of a drug regardless of the outcome of the study.

Safeguards to patients are important. But sound policy action must be informed by sufficient facts.

The Board’s discretionary decision to conduct a Cost Review Study of a drug does not, in and of itself, have any connection to or provide a basis for imposing limitations on utilization management. In conducting the study, the Board seeks to understand whether use of a prescription drug has created an affordability challenge, and then whether policy action, such as setting an upper payment limit, is warranted. The study informs the policy action.

This bill imposes limitations on utilization management and other restrictions based solely on the selection of a drug for study and the action of undertaking that study—regardless of the outcome of the study and any affordability challenge determination. That approach undermines the Board’s processes, devalues the study and may pose significant unintended collateral consequences.

We ask that you oppose House Bill 1440. If you would like to discuss this further, please do not hesitate to contact Christina Shaklee, Health Policy Analyst Advanced at christina.shaklee1@maryland.gov.

Sincerely,

A handwritten signature in black ink, appearing to read "Andrew York", is written over a horizontal line.

Andrew York, Pharm.D., J.D.
Executive Director
Maryland Prescription Drug Affordability Board